Technology developed by Nottingham experts is offering eye-sight saving hope.
A science firm based at MediCity who designed new sight-saving technology is to launch more products which could speed up treatment and so reducing the impact on hospital waiting lists and patient visits.
NuVision has developed the designs from human amniotic membrane donated from caesarean section births. One membrane can potentially save up to 200 peoples’ eyesight and the products can also be used to save animals’ eyesight.
The firm is now launching Omnigen C, for use together with OmniLenz, a bespoke contact lens for the in-clinic application of amnion. A five-minute procedure, it will help medics treat ocular surface diseases immediately.
Omnigen can be used to protect and help restore peoples’ eyesight and the firm says that it’s as quick as a contact lens fittings. and could avoid the need for surgery for certain conditions.
Andrew Hopkinson, chief scientific officer for NuVision, said: “In a post COVID world, NuVision wanted to create something to speed up health procedures, as well as reduce the need for consultation, visits or scheduled surgery time, while improving outcomes for patients.
“It can be used for chemical or thermal burns, new or long-term ocular defects, dry eye disease and ocular inflammation.”
NuVision is one of 23 spin-out companies supported by Nottingham Technology Ventures, a wholly-owned subsidiary of the University of Nottingham which is based in the Ingenuity Centre at the University of Nottingham Innovation Park.
Dr Andy Naylor, the CEO of NTV, said: “NuVision is driving innovation in the field of biotherapies and is a superb example of the University’s spin-out portfolio.
“Health research remains an important priority for the University and it is very exciting to see NuVision deliver technology to market underpinned by University intellectual property.
“The amnion products can be life-changing for many people, and transformational for clinicians and lessen the burden on patient waiting lists."
